Shalini Andersson

Shalini Andersson is a seasoned pharmaceutical executive with extensive experience at AstraZeneca since January 1997, currently serving as Vice President of RNA Gene Cell Therapy at Discovery Sciences. Previous roles include Vice President of Oligonucleotide Discovery and Chief Scientist for New Therapeutic Modalities, where Shalini led strategic initiatives in Nucleic Acid Therapeutics and targeted delivery. In collaboration with Moderna Therapeutics, Shalini served as Project Leader for the mRNA Delivery Platform, and contributed to multiple leadership teams and committees, including the joint steering committee for collaborations with Ionis Pharma and Silence Therapeutics. Earlier in the career, Shalini held several senior director roles focusing on drug metabolism, pharmacokinetics, and new therapeutic modalities. Shalini's academic foundation includes a PhD in Chemistry from Linköping University, where an associate professorship in Organic and Analytical Chemistry was held prior to joining AstraZeneca.